Full capacity utilization in FY27
Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery.
VIDHISPECIALTYFOODINGRED / guidance tracker
Keep management guidance in view.
Vidhi Specialty Food · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Value-added product contribution to double to 10-12% in FY27
Contribution of high-margin value-added products expected to rise from 5% to 10-12% in FY27, with potential for higher if approvals come through.
Capex of ₹75-85 crore for new product line in FY27
Investment in new high-margin product line at Dhar, with commissioning expected in 18 months (H2 FY28). First phase revenue target of ₹125-150 crore.
Pharma coating (Quote Icon) sampling and approvals ongoing
Aggressive sampling with pharma companies; approval cycle ~6 months; initial feedback favorable.